Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer-Reference-Cited by-同舟云学术

Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer

Published:2014-03-26 Issue:10 Volume:5 Page:3145-3158
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Al-Ejeh Fares¹,Miranda Mariska¹²,Shi Wei¹,Simpson Peter T.³,Song Sarah⁴,Vargas Ana Cristina³,Saunus Jodi M.³,Smart Chanel E.³,Mariasegaram Mythily³,Wiegmans Adrian P.¹,Chenevix-Trench Georgia⁵,Lakhani Sunil R.³⁶⁷,Khanna Kum Kum¹²

Affiliation:

1. Signal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia

2. The University of Queensland, St Lucia QLD 4072, Australia

3. The University of Queensland, UQ Centre for Clinical Research, Herston QLD 4029, Australia

4. The University of Queensland, QLD Centre for Medical Genomics, St Lucia QLD 4072, Australia

5. Cancer Genetics Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia

6. The University of Queensland, School of Medicine, Herston QLD 4006, Australia

7. Pathology Queensland: The Royal Brisbane & Women's Hospital, Herston QLD 4029, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERK5 Activity Prevention Improves the Antitumor Efficacy of Fluvastatin on Thymic Carcinoma;Anticancer Research;2024-05-31

2. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival;Cellular and Molecular Life Sciences;2022-09-19

3. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival;2022-05-31

4. BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells;Bioengineered;2022-05-02

5. Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1–S Cell-Cycle Transition;Cancer Research Communications;2022-03-10